Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Xeris Pharmaceuticals Inc (XERS)

Xeris Pharmaceuticals Inc (XERS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 239,446
  • Shares Outstanding, K 26,995
  • Annual Sales, $ 2,470 K
  • Annual Income, $ -60,080 K
  • 60-Month Beta -0.39
  • Price/Sales 95.82
  • Price/Cash Flow N/A
  • Price/Book 5.41

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -1.21
  • Number of Estimates 2
  • High Estimate -1.17
  • Low Estimate -1.24
  • Prior Year -0.98
  • Growth Rate Est. (year over year) -23.47%

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.70 +16.88%
on 11/22/19
9.39 -4.15%
on 11/29/19
+0.98 (+12.22%)
since 11/08/19
3-Month
7.36 +22.28%
on 10/09/19
11.16 -19.38%
on 09/17/19
-0.74 (-7.60%)
since 09/10/19
52-Week
6.85 +31.39%
on 06/06/19
20.79 -56.71%
on 12/18/18
-11.34 (-55.75%)
since 12/10/18

Most Recent Stories

More News
Xeris Pharmaceuticals Announces Positive Topline Results From the In-clinic Stage of the Phase 2 Study of Its Developmental Ready-to-use (RTU) Glucagon in Patients at Risk of Postprandial Hypoglycemia Following Bariatric Surgery

--Rebound hypoglycemia observed more frequently in the placebo arm and with oral glucose tablet use

XERS : 9.00 (+1.47%)
Xeris Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations,...

XERS : 9.00 (+1.47%)
Xeris Pharmaceuticals Provides a Business Update During Recent Investor Conference

MAA submitted to EMA of liquid stable glucagon for severe hypoglycemia

XERS : 9.00 (+1.47%)
Xeris Pharmaceuticals, Inc. (XERS) Reports Q3 Loss, Tops Revenue Estimates

Xeris Pharmaceuticals, Inc. (XERS) delivered earnings and revenue surprises of 3.17% and 61.50%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the...

XERS : 9.00 (+1.47%)
Xeris Pharmaceuticals Reports Third Quarter 2019 Financial Results and Highlights

Gvoke(TM) (glucagon injection) pre-filled syringe (PFS) - now available by prescription

XERS : 9.00 (+1.47%)
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations,...

XERS : 9.00 (+1.47%)
Xeris Pharmaceuticals Appoints Mark Thierer to Board of Directors

Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug...

XERS : 9.00 (+1.47%)
Xeris Pharmaceuticals Begins Dosing Patients in a Phase 2 Clinical Trial Evaluating Its Novel Fixed-Ratio Co-Formulation of Pramlintide-Insulin for Diabetes

Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug...

XERS : 9.00 (+1.47%)
Xeris Pharmaceuticals Announces Expanded $85 Million Debt Facility With Oxford Finance and Silicon Valley Bank

Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug...

XERS : 9.00 (+1.47%)
Xeris Pharmaceuticals Receives U.S. FDA Approval for GVOKE(TM) (glucagon), the First Ready-to-use Stable Liquid Glucagon for Severe Hypoglycemia

--GVOKE is the first premixed, prefilled, premeasured liquid glucagon offering ease of use for pediatric and adult patients with diabetes ages 2 years and above or caregivers to rapidly treat severe hypoglycemic...

XERS : 9.00 (+1.47%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade XERS with:

Business Summary

Xeris Pharmaceuticals, Inc. produces peptides, proteins, antibodies, molecules, auto-injectors, multi-dose pens and infusion pumps to treat endocrine and metabolic diseases. The company's proprietary formulation technologies consist of XeriSol (TM) and XeriJect(TM). Xeris Pharmaceuticals, Inc. is based...

See More

Key Turning Points

2nd Resistance Point 9.45
1st Resistance Point 9.23
Last Price 9.00
1st Support Level 8.83
2nd Support Level 8.66

See More

52-Week High 20.79
Fibonacci 61.8% 15.46
Fibonacci 50% 13.82
Fibonacci 38.2% 12.18
Last Price 9.00
52-Week Low 6.85

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar